Hims & Hers Health (NYSE:HIMS) Stock Price Expected to Rise, Truist Financial Analyst Says

Hims & Hers Health (NYSE:HIMS) had its target price hoisted by investment analysts at Truist Financial from $23.00 to $27.00 in a report released on Friday,Benzinga reports. The firm presently has a “hold” rating on the stock. Truist Financial’s target price points to a potential downside of 5.01% from the company’s previous close.

A number of other research firms have also commented on HIMS. TD Cowen decreased their price objective on shares of Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating for the company in a research note on Friday, March 27th. Zacks Research raised shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research report on Monday, July 13th. Needham & Company LLC raised their price objective on Hims & Hers Health from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Wall Street Zen cut shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Canaccord Genuity Group raised their price objective on shares of Hims & Hers Health from $32.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. Four equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $31.43.

Hims & Hers Health Stock Performance

Shares of HIMS traded down $4.32 during midday trading on Friday, hitting $28.42. 19,157,435 shares of the stock traded hands, compared to its average volume of 27,761,074. The business’s 50 day moving average price is $30.69 and its two-hundred day moving average price is $26.33. Hims & Hers Health has a 1-year low of $13.74 and a 1-year high of $70.43. The firm has a market capitalization of $6.58 billion, a PE ratio of -317.44, a price-to-earnings-growth ratio of 89.16 and a beta of 2.35. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The business had revenue of $608.10 million for the quarter, compared to analyst estimates of $616.84 million. Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. Hims & Hers Health’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same period last year, the business posted $0.20 earnings per share. Equities research analysts predict that Hims & Hers Health will post 0.03 EPS for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, COO Michael Chi sold 14,027 shares of the company’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total transaction of $441,850.50. Following the sale, the chief operating officer directly owned 432,124 shares of the company’s stock, valued at approximately $13,611,906. This represents a 3.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David B. Wells bought 48,400 shares of the business’s stock in a transaction dated Tuesday, May 26th. The stock was purchased at an average price of $24.23 per share, with a total value of $1,172,732.00. Following the purchase, the director directly owned 224,417 shares of the company’s stock, valued at $5,437,623.91. The trade was a 27.50% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders sold 83,126 shares of company stock valued at $2,711,339. 11.76% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC grew its stake in shares of Hims & Hers Health by 25.6% during the fourth quarter. SG Americas Securities LLC now owns 371,553 shares of the company’s stock valued at $12,064,000 after purchasing an additional 75,679 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Hims & Hers Health by 7.2% in the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after buying an additional 1,407,651 shares during the period. Munich Reinsurance Co Stock Corp in Munich bought a new stake in shares of Hims & Hers Health during the fourth quarter worth $11,187,000. Cunning Capital Partners LP bought a new position in Hims & Hers Health in the fourth quarter valued at about $1,110,000. Finally, Virtu Financial LLC acquired a new stake in Hims & Hers Health in the fourth quarter worth about $1,937,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: An FDA advisory panel narrowly backed adding four peptides to a list that could make them eligible for legal compounding, a development that could expand Hims & Hers’ product offerings and boost sales. FDA Panel Narrowly Backs Four Peptides — Hims & Hers Stock in the Spotlight
• Positive Sentiment: Reuters reported that Hims & Hers could tap a potentially multi-billion-dollar peptide market if U.S. regulators loosen manufacturing restrictions, reinforcing the growth narrative behind the stock’s move. Hims & Hers stands to gain if the FDA loosens restrictions on peptides
• Neutral Sentiment: Several follow-up articles and market commentary kept HIMS in the spotlight, but much of the attention was driven by the same FDA peptide decision rather than new company-specific news. Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
• Negative Sentiment: Not all commentary was supportive: Martin Shkreli publicly said he is short Hims & Hers and criticized the company’s peptide products, adding a bearish counterpoint to the bullish FDA-driven narrative. QUICK SPARK: Martin Shkreli Shorts Hims & Hers Stock, Says ‘Peptides Are Fake Medicine’

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.